{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:11Z","timestamp":1792269491492,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01709-y","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:41:43Z","timestamp":1791031303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety Monitoring of COVID-19 Vaccines in the Vaccine Adverse Event Reporting System (VAERS): United States, August 22, 2024\u2013July 4, 2025"],"prefix":"10.1007","author":[{"given":"Brittney","family":"Romanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Strid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Ennulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"1709_CR1","unstructured":"FDA News Release. FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants. August 22, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently."},{"key":"1709_CR2","unstructured":"Food and Drug Administration. COVID-19 vaccines: COVID-19 vaccines authorized for emergency use or FDA-approved. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/novavax-covid-19-vaccine-adjuvanted."},{"key":"1709_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","volume":"73","author":"L Panagiotakopoulos","year":"2024","unstructured":"Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged \u22656 months: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024\u20132025. MMWR Morb Mortal Wkly Rep. 2024;73:819\u201324. https:\/\/doi.org\/10.15585\/mmwr.mm7337e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1709_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","volume":"73","author":"LE Roper","year":"2024","unstructured":"Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:1118\u201323. https:\/\/doi.org\/10.15585\/mmwr.mm7349a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1709_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2019020","author":"PL Moro","year":"2022","unstructured":"Moro PL, McNeil MM. Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines. Expert Rev Vaccines. 2022. https:\/\/doi.org\/10.1080\/14760584.2022.2019020.","journal-title":"Expert Rev Vaccines"},{"issue":"36","key":"1709_CR6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","volume":"33","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398\u2013405. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.035.","journal-title":"Vaccine"},{"key":"1709_CR7","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA\u00ae). https:\/\/www.meddra.org\/."},{"key":"1709_CR8","unstructured":"FDA. CFR\u2013Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?fr=312.32."},{"issue":"2","key":"1709_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","volume":"41","author":"K Moll","year":"2019","unstructured":"Moll K, Lufkin B, Fingar KR, et al. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020. Vaccine. 2019;41(2):333\u201353. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.003.","journal-title":"Vaccine"},{"key":"1709_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15620\/cdc\/174607","volume":"10","author":"B Tejada-Vera","year":"2025","unstructured":"Tejada-Vera B, Bastian BA, Curtin SC. Deaths: leading causes for 2023. Natl Vital Stat Rep. 2025;10:1. https:\/\/doi.org\/10.15620\/cdc\/174607.","journal-title":"Natl Vital Stat Rep"},{"issue":"15","key":"1709_CR11","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","volume":"41","author":"MS Gold","year":"2023","unstructured":"Gold MS, Amarasinghe A, Greenhawt M, et al. Anaphylaxis: revision of the Brighton collaboration case definition. Vaccine. 2023;41(15):2605\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.027.","journal-title":"Vaccine"},{"issue":"3","key":"1709_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599\u2013612. https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.003.","journal-title":"Vaccine"},{"issue":"4","key":"1709_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2020","unstructured":"Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2020;327(4):331\u201340. https:\/\/doi.org\/10.1001\/jama.2021.24110.","journal-title":"JAMA"},{"key":"1709_CR14","unstructured":"U.S. Census Bureau. Age and sex. American Community Survey, ACS 1-year estimates subject tables, Table S0101; 2024 [cited 2026 Jun 4]. https:\/\/data.census.gov\/table\/ACSST1Y2024.S0101."},{"key":"1709_CR15","unstructured":"National Center for Immunization and Respiratory Diseases. Weekly parental intent for vaccination and cumulative percentage of children 6 months\u201317 years who are up to date with the COVID-19 vaccines by season, United States [Public Health Surveillance Dataset] [Internet]. data.cdc.gov; 2026 [cited 2026 Jun 8]. https:\/\/data.cdc.gov\/Child-Vaccinations\/Weekly-Parental-Intent-for-Vaccination-and-Cumulat\/ker6-gs6z\/about_data."},{"key":"1709_CR16","unstructured":"National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention. COVID-19 vaccination coverage, overall and by selected demographics and jurisdiction, among adults 18 years and older, by season. Atlanta (GA): Centers for Disease Control and Prevention; 2026 [cited 2026 Jun 4]. https:\/\/data.cdc.gov\/Vaccinations\/COVID-19-Vaccination-Coverage-Overall-and-by-Selec\/ksfb-ug5d\/about_data."},{"issue":"2","key":"1709_CR17","doi-asserted-by":"publisher","first-page":"e2253845","DOI":"10.1001\/jamanetworkopen.2022.53845","volume":"6","author":"WE Abara","year":"2023","unstructured":"Abara WE, Gee J, Marquez P, et al. Reports of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the United States. JAMA Netw Open. 2023;6(2):e2253845. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.53845.","journal-title":"JAMA Netw Open"},{"key":"1709_CR18","unstructured":"CFR part 46.102(l)(2), 21 CFR part 56, 42 USC \u00a7241(d), 5 USC \u00a7552a, and 44 USC \u00a73501 et seq."},{"key":"1709_CR19","unstructured":"CDC. COVIDVaxView. Weekly COVID-19 vaccination dashboard. May 7, 2025. https:\/\/www.cdc.gov\/covidvaxview\/weekly-dashboard\/index.html."},{"key":"1709_CR20","unstructured":"Package-Insert-COMIRNATY (fda.gov) https:\/\/www.fda.gov\/vaccines-blood-biologics\/comirnaty"},{"key":"1709_CR21","unstructured":"Shimabukuro T. COVID-19 safety update. Oral presentation at the advisory committee on immunization practices (ACIP) meeting, March 1, 2021. https:\/\/stacks.cdc.gov\/view\/cdc\/105736."},{"issue":"10342","key":"1709_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","volume":"399","author":"HL Wong","year":"2022","unstructured":"Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(22)00791-7.","journal-title":"Lancet"},{"issue":"3","key":"1709_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/infdis\/jiaa543","volume":"223","author":"S Perez-Vilar","year":"2021","unstructured":"Perez-Vilar S, Hu M, Weintraub E, et al. Guillain-Barr\u00e9 syndrome after high-dose influenza vaccine administration in the United States, 2018\u20132019 Season. J Infect Dis. 2021;223(3):416\u201325. https:\/\/doi.org\/10.1093\/infdis\/jiaa543.","journal-title":"J Infect Dis"},{"key":"1709_CR24","unstructured":"Lloyd P. Evaluation of Guillain-Barr\u00e9 Syndrome (GBS) following respiratory syncytial virus (RSV) vaccination among adults 65 years and older. In: Advisory Committee on immunization practices (ACIP) meeting. June 26, 2024 https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/06-RSV-Adult-Lloyd-508.pdf."},{"key":"1709_CR25","unstructured":"Panagiotakopoulos L. Use of 2025-2026 COVID-19 vaccines: Work Group Considerations. Oral Presentation at the Advisory Committee on Immunization Practices (ACIP) Meeting, April 15, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/05-Panagiotakopoulos-COVID-508.pdf."},{"key":"1709_CR26","doi-asserted-by":"publisher","unstructured":"Gee J, Shimabukuro TT, Su JR, et al. Overview of US COVID-19 vaccine safety surveillance systems. Vaccine. 2024.\nhttps:\/\/doi.org\/10.1016\/j.vaccine.2024.02.065. (\nPublished online April 16, 2024).","DOI":"10.1016\/j.vaccine.2024.02.065"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01709-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:02:23Z","timestamp":1791075743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01709-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":26,"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01709-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The findings and conclusions in this manuscript are those of the author and do not necessarily represent the official position of the CDC","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This activity was reviewed by the CDC and was considered to be consistent with applicable federal law and CDC policy. Informed consent was not obtained for this secondary use of existing information; see 45 CFR part 46.102(l)(2), 21 CFR part 56, 42 USC \u00a7241(d), 5 USC \u00a7552a, and 44 USC \u00a73501 et seq.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from the VAERS system is available to everyone through the VAERS Wonder database available at:\n                      \n                      . Anyone with internet access may reach this site and conduct basic analysis to confirm some of the findings described in the manuscript. However there is data in this manuscript which comes from review of medical records of the patients who experienced an adverse event. This data cannot be shared openly to protect patient privacy.","order":6,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BR and PLM originated the study, supervised its implementation, conducted the analysis, and led the writing of the manuscript summarizing the findings. PS, AH, ES, PM, BZ, CE, HB, and JS assisted in one or more aspects, including study design, review of VAERS reports and medical records, technical advice, administrative support, and writing of the report. All authors read and approved the final version.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}